These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12134370)

  • 1. Radiology and "pet" names.
    Collins J
    Semin Roentgenol; 2002 Apr; 37(2):97. PubMed ID: 12134370
    [No Abstract]   [Full Text] [Related]  

  • 2. How should we introduce clinical PET in the UK? The oncologists need to have a view.
    Price P; Laking G
    Clin Oncol (R Coll Radiol); 2004 May; 16(3):172-5. PubMed ID: 15191003
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrer's perspective.
    Gopalan D; Griffiths D; Townsend C; Prvulovich E; Bomanji J; Costa DC; Ell PJ
    Nucl Med Commun; 2002 Nov; 23(11):1041-6. PubMed ID: 12411831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
    Menda Y; Graham MM
    Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission and computed X-ray tomography: a coming together.
    Costa DC; Visvikis D; Crosdale I; Pigden I; Townsend C; Bomanji J; Prvulovich E; Lonn A; Ell PJ
    Nucl Med Commun; 2003 Apr; 24(4):351-8. PubMed ID: 12673162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical PET in the UK: dangers of missing an opportunity.
    O'Doherty MJ
    Nucl Med Commun; 2001 Jul; 22(7):737-9. PubMed ID: 11453044
    [No Abstract]   [Full Text] [Related]  

  • 7. Is whole-body FDG-PET valuable for health screening? Against.
    Weckesser M; Schober O
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):342-3. PubMed ID: 15726351
    [No Abstract]   [Full Text] [Related]  

  • 8. PET evaluation of lung cancer.
    Bunyaviroch T; Coleman RE
    J Nucl Med; 2006 Mar; 47(3):451-69. PubMed ID: 16513615
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of FDG PET in the management of lymphoma: practical guidelines.
    Kirby AM; George Mikhaeel N
    Nucl Med Commun; 2007 May; 28(5):355-7. PubMed ID: 17414884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early clinical experience and impact of [18F]fluorodeoxyglucose positron emission tomography.
    Akpinar AT
    Nucl Med Commun; 2006 Apr; 27(4):405. PubMed ID: 16531929
    [No Abstract]   [Full Text] [Related]  

  • 11. Is whole-body FDG-PET valuable for health screening? For.
    Ide M; Suzuki Y
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):339-41. PubMed ID: 15726352
    [No Abstract]   [Full Text] [Related]  

  • 12. Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma.
    Xu YH; Shen CT; Xue YL; Qiu ZL; Luo QY
    Hell J Nucl Med; 2013; 16(3):199-203. PubMed ID: 24251307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET: too much of a good thing? Does the plethora of choices impact on patient management?
    Divgi C; Pandit-Taskar N
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):398. PubMed ID: 15761778
    [No Abstract]   [Full Text] [Related]  

  • 14. 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?
    Weber WA
    J Nucl Med; 2007 Oct; 48(10):1580-2. PubMed ID: 17909256
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical PET: are we ready?
    Coleman RE; Tesar RD
    J Nucl Med; 1997 Dec; 38(12):16N, 24N. PubMed ID: 9430451
    [No Abstract]   [Full Text] [Related]  

  • 16. HCFA approves Medicare coverage of PET scans.
    Cave L
    J Natl Cancer Inst; 2001 Feb; 93(3):177. PubMed ID: 11158185
    [No Abstract]   [Full Text] [Related]  

  • 17. Positron emission tomography and bone metastases.
    Fogelman I; Cook G; Israel O; Van der Wall H
    Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
    Larson SM; Schwartz LH
    J Nucl Med; 2006 Jun; 47(6):901-3. PubMed ID: 16741296
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".
    Higashi T; Saga T; Nakamoto Y; Ishimori T; Fujimoto K; Doi R; Imamura M; Konishi J
    Ann Nucl Med; 2003 Jun; 17(4):261-79. PubMed ID: 12932109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nodules, CT-scans and PET-scans: a good partnership.
    Vansteenkiste JF
    Lung Cancer; 2004 Jul; 45(1):29-30. PubMed ID: 15196731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.